Diseases of the circulatory system are the leading cause of mortality in the world. Only in Russia, its percentage reaches 56% in the structure of total mortality, leaving far behind such causes as neoplasms (16%), respiratory diseases (8%) or digestion (7%)². And it is the high mortality rate from CVD that makes the main contribution to the low life expectancy in the Russian Federation. The burden of atherosclerosis and dyslipidemia in the Russian Federation is extremely high. Unfortunately, Russia is among the leaders in cardiovascular diseases (CVD) in general,  and coronary heart disease (CHD) and strokes in particular.

Convincing data from various clinical studies show that lowering total cholesterol is the most powerful factor influencing mortality rates from coronary artery disease³. In particular, it was found that a decrease in low-density lipoprotein cholesterol (LDL-C) for every 1 mmol/L leads to a reduction in the risk of myocardial infarction (-23%), cardiovascular death (-19%) and overall death (-12%)⁴.

According to the Clinical Guidelines of the Ministry of Health of the Russian Federation "Lipid Metabolism Disorders" of 2023, statins 5 are the drugs of choice for achieving LDL-C targets. However, if statin monotherapy does not achieve the goal, combination therapy of statin with ezetimibe should be considered, preferably in a single tablet or capsule (in very high-risk individuals, it is recommended to start lipid-lowering therapy immediately with a combination of statin and ezetimibe)5.

Krzysztof Skup, General Director of EGIS-RUS LLC: "We are convinced that modern therapies, especially in such a complex area as cardiology, should work like the thinnest surgical instrument - to act as precisely as possible and at the same time safely for the patient. Primary hypercholesterolemia is exactly the type of pathology when the effectiveness of therapy depends to the greatest extent on the correct selection of the drug, dosage and adherence to long-distance treatment. There are two FDCs in EGIS lipid portfolio: statin + ezetimibe and rosuvastatin + ezetimibe - the latest registered combination. We hope that thanks to our developments, doctors will be able to more individually approach the prescription of dosages, and patients will have more opportunities to achieve LDL-C targets and improve their quality of life."

 SIDE EFFECTS MAY OCCUR. IT IS NECESSORY TO CONSULT A HEALTHCARE SPECIALIST.

1. State Register of Medicines [Electronic Resource] (Access Date 14.04.2023) URL: https://grls.rosminzdrav.ru/grls.aspx

2. Federal State Statistics Service [Electronic Resource] (Access Date 14.04.2023) URL: https://rosstat.gov.ru/folder/12781 (Access Date 19.04.2023)

3.       Ford E.S., et al. Explaining the decrease in US deaths from coronary disease, 1980–2000 // New England Journal of Medicine. 2007. Т. 356. №. 23. С. 2388–2398.

4.       Baigent C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005 Oct 8; 366(9493): 1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.

5. Clinical recommendations 752. Disorders of lipid exchange. Approved by the scientific and practical council of the Ministry of Health of the Russian Federation.

[Electronic resource] (Access date 14.04.2023) cr.minzdrav.gov.ru/recomend/752_1